[HTML][HTML] miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway
J Liu, Y Xing, L Rong - Oncology reports, 2018 - spandidos-publications.com
A number of miRNAs have been found to be abnormally expressed or mutated in numerous
cancers and thus, are considered to act as oncogenes or tumor suppressor genes. The aim …
cancers and thus, are considered to act as oncogenes or tumor suppressor genes. The aim …
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung …
PL Su, YL Wu, WY Chang, CL Ho… - Therapeutic …, 2018 - journals.sagepub.com
Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
MicroRNA-25-3p promotes cisplatin resistance in non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route
B Sun, N Hu, D Cong, K Chen, J Li - Bioengineered, 2021 - Taylor & Francis
MicroRNAs exert crucial effects in the drug resistance. The purpose of this research was to
investigate the miR-25-3p effects on DDP resistance in NSCLC. We used RT-qPCR to …
investigate the miR-25-3p effects on DDP resistance in NSCLC. We used RT-qPCR to …
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell …
N Aiko, T Shimokawa, K Miyazaki, Y Misumi, Y Agemi… - BMC cancer, 2018 - Springer
Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
The influence of intervening on the pharmaceutical consultation targeting outpatients with advanced non-small cell lung cancer receiving erlotinib treatment
S Nishibe-Toyosato, Y Ando, Y Goto… - Biological and …, 2021 - jstage.jst.go.jp
Erlotinib is used to treat advanced non-small-cell lung cancer (NSCLC), the common serious
adverse events are skin disorders. The dose intensity of erlotinib should be maintained as …
adverse events are skin disorders. The dose intensity of erlotinib should be maintained as …
[HTML][HTML] Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective …
K Yoshida, S Kanda, H Shiraishi, K Goto… - Journal of Thoracic …, 2019 - ncbi.nlm.nih.gov
Background Central nervous system (CNS) metastasis is a poor prognostic factor in patients
with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
Algoritmo para el diagnóstico preliminar de caries y área afectada del diente en base al algoritmo de búsqueda de pixeles y la librería Skimage
JA Cuellar Pinedo, ME Peña Parco - 2019 - repositorio.ucv.edu.pe
La presente investigación abarcó el desarrollo de un sistema experto para el diagnóstico
preliminar de caries. El objetivo de la investigación fue determinar la precisión del …
preliminar de caries. El objetivo de la investigación fue determinar la precisión del …
What is the best drug as a front-line treatment for EGFR activating mutation?
H Uramoto - Precision Cancer Medicine, 2018 - pcm.amegroups.org
The landscape of lung cancer treatment is dramatically changing. Non-small cell lung
cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations are …
cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations are …
[PDF][PDF] Naoto Aiko1, Tsuneo Shimokawa1, Kazuhito Miyazaki1, Yuki Misumi1, Yoko Agemi1, Mari Ishii2, Yukiko Nakamura1
T Yamanaka, H Okamoto - 2018 - bmccancer.biomedcentral.com
Background: Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …